Day: September 30, 2024

BEDMINSTER, NJ, Sept. 30, 2024 (GLOBE NEWSWIRE) — Peapack-Gladstone Financial Corporation (“the Company”) (NASDAQ Global Select Market:  PGC) reports today that Moody’s Investors Service (“Moody’s”) has confirmed investor grade ratings for both the Company and its banking subsidiary, Peapack-Gladstone Bank (“the Bank”). Moody’s has confirmed the Baa3 long term local currency issuer rating for the Company, and the baa2 baseline credit assessment (BCA) for the Bank. The outlooks on the long-term issuer rating of the Company and on the long-term deposits and issuer ratings of Peapack-Gladstone Bank have been changed to “stable” from ratings under review. These actions conclude the review for possible downgrade that was initiated back in June of this year. To establish the rating, Moody’s extensively reviewed the business fundamentals...

ŽEMAITIJOS PIENAS AB (hereinafter – the Company) provide I-st half-year of 2024 information: (i) a set of consolidated financial statements for the first half of the financial year; (ii) a consolidated half-year report; and (iii) approval of the responsible persons. The person authorized to provide additional information: Arnas MatuzasHead of LegalE-mail: a.matuzas@zpienas.lt  AttachmentsApproval of the responsible personsConsolidated semi-annual reporta set of consolidated financial statements for the first half of the financial year

DawnDawnmyAirMyAirLUXELUXEResMed makes it easier for people to manage their sleep health and stay on (continuous positive airway pressure) CPAP treatment by integrating its leading myAir™ consumer app with Apple and Android smartwatches.Introduces a Generative AI-enabled sleep health assistant to guide people on their journey to better sleep and new travel gear to help people stay on CPAP treatment while traveling.SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) — ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These innovations integrate with digital wearable devices and generative artificial intelligence...

30th September 2024, 15:45 CET On the occasion of the 20th anniversary of ArcelorMittal Poland, ArcelorMittal Europe CEO Geert Van Poelvoorde calls for European Union support for emergency trade measures, and a firm action plan for steel, to keep steelmaking alive in Europe It is 20 years since Mittal Steel acquired Polskie Huty Stali in 2004, when the business was put up for privatisation by the Polish government. Since then, the business has been transformed and modernised through significant investment. Today in Poland, ArcelorMittal has Europe’s most modern hot rolling mill, in Kraków; the heavy section mill in Dąbrowa Górnicza is in the elite group of mills able to produce 120-metre-long rail. Carbon dioxide emissions have been reduced by 42 percent, dust emissions by 90 percent, and energy consumption by 40 percent. According to...

Amsterdam and Dubai, 30 September 2024: VEON Ltd. (Nasdaq: VEON, Euronext Amsterdam: VEON), a global digital operator, is pleased to announce the appointment of two new senior executives to its Group Leadership Team in Dubai. Anand Ramachandran, who joins VEON as the Chief of Staff to the Group CEO, and Inanc Cakiroglu, who joins as the Group Chief Information Officer (CIO), will both be based in VEON’s expanding operational hub in Dubai, and report to Group CEO Kaan Terzioglu. “As we have shared with our investors on VEON’s Capital Markets Day, we are bullish about growth and have set out an ambitious vision for the upcoming three years. In this new era, VEON will grow by putting a more granular focus on our digital big bets, as well as consumer and enterprise services, making the full potential of various verticals in our business visible...

NEW YORK, NY, Sept. 30, 2024 (GLOBE NEWSWIRE) — Image Protect, Inc. (OTC:IMTL) (Imageprotectcorporation.com) (“Image Protect” or the “Company”), through its subsidiaries, Review Control Reputation Management and 2CentTexts.com, is happy to inform shareholders that it is moving forward with development of its new Generative AI programming to help clients assimilate important consumer data to assist in targeted marketing campaigns. This is a very lucrative and logical next step in the company’s quest to provide the very best in digital management tools for its valued customers and will seamlessly bring together the most important aspects of the company’s two main subsidiaries, creating better results for its clients and an additional revenue-generating service. Incoming CEO Frank Casella said: “With all our combined services, including...

Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs HOUSTON, Sept. 30, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2024 Cell & Gene Meeting on the Mesa Conference taking place October 7-9 in Phoenix, Arizona. “We always look forward to attending this very informative and collaborative meeting. For this year’s meeting we will present an update of our pre-clinical IND-enabling studies in chronic wound healing and psoriasis as we prepare for a...

FDA confirms that SciSparc’s study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that the U.S. Food and Drug Administration (“FDA”) has confirmed that its investigational new drug (“IND”) application for its first in class drug candidate SCI-110 study may proceed with its Phase IIb clinical trials in the U.S. in adults patients with Tourette Syndrome (“TS”). This previously announced FDA approval is one of the most important milestones of SciSparc to date. Oz Adler, Chief Executive Officer of SciSparc, commented “As the currently...

– Fourth Quarter 2024 Revenue Estimated $9 Million – Full Year 2024 Revenue Estimated $22 Million LOS ANGELES, Sept. 30, 2024 (GLOBE NEWSWIRE) — Crown Electrokinetics Corp. (NASDAQ:CRKN) (“Crown” or the “Company”), a leading smart glass technology company and an expert in constructing fiber optic networks and lead pipe inspection and remediation, today provided fourth quarter and full year fiscal 2024 revenue guidance of $9 million, resulting in estimated 2024 fiscal year revenues of approximately $22 million. In addition to investing in and growing its business portfolio, Crown has significantly narrowed its gap to profitability compared to the first half of fiscal 2024. “We recognize the balance between growth and achieving profitability. Our investments in people, equipment, and process over the last...